Forté Pharma strengthens cosmetics range with oral supplement launch

20 Jan 2020

Reig Jofre's oral, anti-wrinkle, moisturizing and firming cosmetic expands Forté Pharma's beauty range.

Forté Pharma, Reig Jofre's line of nutritional supplements, has expanded its range of beauty products with the launch in Spain, France and Belgium of Expert Lift’ Filler, a new nutritional supplement in the form of a drinkable stick designed to reduce the volume of wrinkles and moisturize and firm the skin.

Forté Pharma strengthens cosmetics range with oral supplement launch

Scientific studies have proven and measured a reduction of wrinkle volume of up to 50% after an 8-week intake. They also confirm the effectiveness of the product’s formula, which contains a high concentration of bioactive collagen that improves skin elasticity, hyaluronic acid that contributes to the maintenance of good hydration, vitamins A, C and E, and the minerals selenium and manganese, which provide antioxidant protection and prevent skin ageing.

The oral cosmetics market is growing, representing sales of more than 25 million euros in France, a market in which Forté Pharma is among the leading companies in the sector.

Forté Pharma currently organizes its product portfolio in four ranges: beauty (13% of sales), weight control (36%), energy (27%), and health (24%) at the end of December 2019.

Read More

Related news

UPDATED: COVID-19 PHARMA TRACKER

UPDATED: COVID-19 PHARMA TRACKER

27 Mar 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…

Read more 
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Read more 
ProBioGen selected for development and large-scale manufacturing services

ProBioGen selected for development and large-scale manufacturing services

24 Mar 2020

The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.

Read more 
Positive update on the development of new XF‐platform drug formulations

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more 
Alvotech and DKSH partner to bring key biosimilar to Asia

Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Read more 
Helsinn receives European approval of its IV formulation of Akynzeo

Helsinn receives European approval of its IV formulation of Akynzeo

23 Mar 2020

The new formulation offers patients in Europe an alternative route of administration of the only fixed antiemetic combination targeting two distinct CINV pathways in a single dose.

Read more 
Lonza's new medium boosts and optimizes AAV production in insect cells

Lonza's new medium boosts and optimizes AAV production in insect cells

23 Mar 2020

The TheraPEAK SfAAV Medium is specifically designed to support the development of safe, scalable, gene therapies.

Read more 
Codexis and Takeda collaborate to advance novel gene therapies

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Read more 
Oxford Biomedica signs LSA with Juno Therapeutics

Oxford Biomedica signs LSA with Juno Therapeutics

19 Mar 2020

Cell and gene focused CDMO Oxford Biomedica (OXB) has signed a licence and clinical supply agreement which could be worth up to USD227 million with Juno Therapeutics, the firms announced Wednesday.

Read more 
FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment

FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment

19 Mar 2020

Fujifilm Diosynth Biotechnologies will triple microbial production capacity at its UK Teesside facility after joint owner Fujifilm Corporation pledged to invest 9 billion yen (USD83 million) in the biologics focused CDMO.

Read more